FDA approved durvalumab for resectable non-small cell lung cancer in 2024
The approval covers neoadjuvant chemotherapy plus durvalumab followed by adjuvant single-agent durvalumab after surgery.
On August 15, 2024, the FDA approved durvalumab, sold as Imfinzi by AstraZeneca, for use with platinum-containing chemotherapy as a neoadjuvant treatment, followed by durvalumab alone as adjuvant treatment following surgery. The approval applies to adults with resectable non-small cell lung cancer, defined as tumors measuring at least 4 cm and/or with node-positive disease.1
The regimen combines chemotherapy and immunotherapy before surgery with a period of durvalumab monotherapy afterward, according to the FDA's description of the approved use.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.